SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland
11 references·0 citing·38 second hop
Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland (2022)Value and Price of Multi-indication Cance…Unmet Medical Need: An Introduction to Definitions and Stakeholder Perceptions (2019)Unmet Medical Need: An Introd…Does external reference pricing deliver what it promises? Evidence on its impact at national level (2019)Does external reference prici…The FDA Breakthrough-Drug Designation — Four Years of Experience (2018)The FDA Breakthrough-Drug Des…Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries (2017)Using health technology asses…The Economics of Indication-Based Drug Pricing (2017)The Economics of Indication-B…Indication-Specific Pricing for Cancer Drugs (2014)Indication-Specific Pricing f…Dealing with uncertainty and high prices of new medicines: A comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden (2014)Dealing with uncertainty and …Managed entry agreements for pharmaceuticals: the European experience (2013)Managed entry agreements for …Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation (2013)Early benefit assessment (EBA…Differences in costs of and access to pharmaceutical products in the EU (2011)Differences in costs of and a…The Economic Value of Innovative Treatments over the Product Life Cycle: The Case of Targeted Trastuzumab Therapy for Breast Cancer (2009)The Economic Value of Innovat…Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers (2010)Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers (2010)Performance-Based Risk-Sharing Arrangements—Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force (2013)Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks (2017)Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future (2017)Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy (2023)Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs (2009)Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer (2015)A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non–Small Cell Lung Cancer (2017)Value-Based Pricing for Drugs (2018)International Journal of Technology Assessment in Health Care (review) (1987)Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets (2018)A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) (2015)American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options (2015)Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold (2015)Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: The Advance Value Framework (2017)Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward (2019)A Health Opportunity Cost Threshold for Cost-Effectiveness Analysis in the United States (2020)New FDA Breakthrough-Drug Category — Implications for Patients (2014)Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review (2017)The impact of price regulation on the launch delay of new drugs—evidence from twenty‐five major markets in the 1990s (2004)Greece: Health System Review. (2010)The Netherlands: health system review. (2010)Intergenerational Equity: An Exploration of the ‘Fair Innings’ Argument (1997)Effectiveness and efficiency of search methods in systematic reviews of complex evidence: audit of primary sources (2005)What Is Real-World Data? A Review of Definitions Based on Literature and Stakeholder Interviews (2017)Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis (2020)Prevalence of unmet health care need in older adults in 83 countries: measuring progressing towards universal health coverage in the context of global population ageing (2023)Structured content and data management—enhancing acceleration in drug development through efficiency in data exchange (2023)Underuse of generic medicines in Portugal: An empirical study on the perceptions and attitudes of patients and pharmacists (2011)Does deregulation in community pharmacy impact accessibility of medicines, quality of pharmacy services and costs? Evidence from nine European countries (2014)Causes of drug shortages in the legal pharmaceutical framework (2015)De innovatione: The concept of innovation for medical technologies and its implications for healthcare policy-making (2015)Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia (2016)A Comparison of Reimbursement Recommendations by European HTA Agencies: Is There Opportunity for Further Alignment? (2017)Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma (2018)Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer (2018)Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications (2021)
this work references cited by second hop

References

  • 2017Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries306 cited
  • 2013Managed entry agreements for pharmaceuticals: the European experience167 cited
  • 2014Dealing with uncertainty and high prices of new medicines: A comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden156 cited
  • 2014Indication-Specific Pricing for Cancer Drugs128 cited
  • 2019Unmet Medical Need: An Introduction to Definitions and Stakeholder Perceptions125 cited
  • 2013Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation90 cited
  • 2011Differences in costs of and access to pharmaceutical products in the EU89 cited
  • 2017The Economics of Indication-Based Drug Pricing79 cited
  • 2019Does external reference pricing deliver what it promises? Evidence on its impact at national level75 cited
  • 2018The FDA Breakthrough-Drug Designation — Four Years of Experience61 cited
  • 2009The Economic Value of Innovative Treatments over the Product Life Cycle: The Case of Targeted Trastuzumab Therapy for Breast Cancer57 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work